Jobs posted by Erasmus MC

Mimir provides the automated job management of jobs on job boards for Erasmus MC.

Latest jobs

PhD-student on cellular responses to DNA damage-induced transcription stress

Correct transcription by RNA polymerase II (Pol II) to generate RNA is crucial for proper cell function. However, the DNA transcribed by Pol II is continuously compromised by DNA damage that can block transcription. These transcription-blocking DNA lesions (TBLs) can cause cellular dysfunction and cell death, eventually resulting in DNA damage-induced aging and genome instability. Cells counteract these deleterious effects by transcription-coupled repair (TCR), which specifically removes TBLs thereby safeguarding transcription. Our lab has identified several important factors in this repair pathway (Schwertman et al. Nature Genetics, 2012; Dinant et al. Molecular Cell, 2013 and Tresini et al. Nature, 2015, Steurer PNAS, 2018).

Surprisingly little is known about the molecular consequences of DNA damage that blocks transcription, or how transcription is inhibited and subsequently restarted following DNA repair. Using a combination of CRISPR-Cas9 technology with genetics, proteomics and live-cell imaging approaches the PhD student will identify new factors and dissect the molecular mechanism how cells cope with the detrimental effects of transcription-blocking DNA damage and their role in DNA damage-induced aging.

38 applications

16-01-2020 Erasmus MC
PhD student on the development of oncolytic viro-immunotherapy for treatment of patients with pancreatic-, prostate and brain cancer.

Objective: In the last few decades tremendous progress has been made in the treatment of cancer thereby improving the prognosis of many cancer patients. Despite the progress in the treatment of cancer, there are still only limited effective treatment options for various aggressive cancer types such as pancreatic cancer, advanced prostate cancer and glioblastoma. New treatment options are desperately needed. Oncolytic viro-immunotherapy, based on oncolytic viruses constitutes such a novel treatment option. Viro-immunotherapy results in direct tumour cell killing and local inflammation, which in turn leads to activation of the adaptive immune system.

To rapidly develop and implement viro-immunotherapy as a treatment modality for cancer, we collaborate in the Dutch Oncolytic Viro-Immuno Therapy consortium (OVIT) in which the necessary expertise in virology, immunology, immunotherapy and the clinic is bundled. The aim of this consortium is to develop an efficacious and safe viro-immunotherapy for patients with pancreatic-, prostate and brain cancer, using three oncolytic viruses: Newcastle disease virus, reovirus and adenovirus. The efficacy of oncolytic viro-immunotherapy varies between patients, depending on the tumor type and the applied oncolytic virus. The observed heterogeneous anti-tumor responses to oncolytic viruses emphasize the clinical need for better stratification of cancer patients for viro-immunotherapy by selecting the most promising candidate OV in future clinical trials.

The PhD project, focusing on pancreatic tumors and Newcastle disease virus, is part of the StratiVIR program. This program aims to develop and implement assays that contribute to better stratification of individual cancer patients for future clinical virotherapy studies. Within the PhD project, you will manipulate and generate viruses with aid of reverse genetics techniques, evaluate selected viruses for efficacy and safety in in vitro and in vivo models for the afore mentioned tumours. In parallel, you will establish near-patient-disease models for pancreatic cancer, i.e. organoids and/or ex vivo tumor slices, for which you will conduct molecular profiling to identify predictive tumor gene expression signatures for the selection of the best available OV for treatment of individual patients.

The PhD project is funded by Support Casper, which is a crowdfunding organisation for treatment of patients with pancreatic tumors.

74 applications

15-01-2020 Erasmus MC
Post-doctoral position – applied physicist/biomedical engineer

The goal of the project "Improving surgical removal of oral cancer using a unique, innovative combination of fluorescence-guided surgery and Raman spectroscopy", is to increase the surgical success rate of tumor resections. Our research group has developed Raman spectroscopic instrumentation, measurement strategies, and real-time data-analysis for rapid intra-operative inspection of the entire resection surface of tumor resection specimens. The goal of this project is to adjust these systems in a way to make them compatible with the use of exogenous tumor-specific fluorescent targeting agents that are systemically injected pre-operatively to facilitate fluorescence-guided surgery. You will work in a multidisciplinary project team, comprised of surgeons, pathologists, engineers, and Raman spectroscopists, with day-to-day responsibility for the project.

You will help to develop new applications for research grants and contribute to intermediate reporting to the subsidy provider. You will have the lead in analyzing and interpretation of data, writing scientific articles and communicating study results at relevant national and international conferences.

19 applications

10-01-2020 Erasmus MC
PhD students on project “SYMPHONY: Orchestrating personalized treatment for patients with bleeding disorders”

The aim of the project "SYMPHONY: Orchestrating personalized treatment for patients with bleeding disorders" is to establish best treatment choice for each individual with a bleeding disorder based on bleeding tendency. This will be achieved by improving current diagnostic tests to measure hemostatic potential and by performing fundamental research into the pathophysiology behind interindividual differences in bleeding phenotype and treatment response, using novel techniques such as proteomics, and both IPSc and endothelial cellular systems.

This will be achieved by intensive collaborations between the twelve workpackages (WP) (14 fte PhD and 1 fte postdoc), divided into three themes: Diagnostics, Treatment and Fundamental research. Clinical research will focus on a.o.:

  • Treatment optimization by personalization, increasing quality of care at acceptable costs;
  • Guidance of complex clinical shared decision making for novel therapeutic options;
  • Patient-orchestrated implementation of health care innovations using e-health modules.

The SYMPHONY consortium is a broad interdisciplinary cooperation consisting of diverse disciplines: (Pediatric) Hematology, Vascular Medicine, Clinical Genetics, Clinical Pharmacology, Psychology, Ethics, Epidemiology & Methodology, Mathematics, Health Care Economics, Information & Data Technology, Biochemistry, Molecular Biology, Molecular Genetics and Cell Biology, Laboratory Medicine, Business Economics, Marketing, Sales & Patient Advocacy.

For this project a total of 14 PhD's will be hired, these are the vacancies within the Erasmus MC:

  • WP03 - Novel diagnostic assays for coagulation factor deficiencies
  • WP05 - Establishing a value-based health care approach
  • WP06 - Dose individualization of factor concentrates and desmopressin using population pharmacokinetic (PK) modelling
  • WP08 - Costs and effects of personalized treatment in bleeding disorder patients

For details and to apply, please visit the SYMPHONY website.

16 applications

06-01-2020 Erasmus MC
Junior onderzoeker

De GOUD studies worden reeds verricht binnen de gelijknamige Academische Werkplaats, bestaande uit 3 grote zorgorganisaties voor mensen met een verstandelijke beperking (Abrona, Amarant, Ipse de Bruggen) en de Leerstoel Geneeskunde voor Verstandelijk Gehandicapten in het Erasmus MC. Omdat de zorgorganisaties niet over voldoende deelnemers beschikken wil de Academische Werkplaats samen gaan werken met andere zorgorganisaties.

De junior onderzoeker zal alle uitvoerende taken van de onderzoekers binnen de nieuw deelnemende zorgorganisaties verrichten, onder begeleiding van het huidige team van promovendi, postdocs en UD's. In eerste instantie is deze uitbreiding van toepassing op de Antipsychotica afbouwstudie, eventueel kan deze werkwijze ook voor andere studies toegepast worden. Aanvullende informatie is te vinden op de website goudonbeperktgezond.

Antipsychotica afbouwstudie: In de zorg voor mensen met een verstandelijke beperking wordt vaak antipsychotica voorgeschreven voor de behandeling van gedragsproblemen. De werkzaamheid van deze behandeling is niet bewezen, maar in de praktijk blijkt dat het afbouwen van antipsychotica vaak moeilijk gaat. In de antipsychotica afbouwstudie wordt onderzocht waarom dat zo moeilijk gaat. Tijdens deze periode worden metingen verricht om gedrag, psychiatrische stoornissen, slaap, en bijwerkingen / afbouwverschijnselen in kaart te brengen. Deze metingen zullen plaatsvinden in de zorgorganisaties. De metingen zullen lopen tot het voorjaar van 2021.
Als junior onderzoeker ben je verantwoordelijk voor het zelfstandig organiseren en uitvoeren van het onderzoek binnen de samenwerkende zorgorganisaties. Je werkt nauw samen met de GOUD-onderzoekers en jullie zijn samen het eerste aanspreekpunt voor deze studie.

7 applications

02-01-2020 Erasmus MC